Amniotics AB
Jan F Talts has extensive work experience in the field of science and operations. Jan F currently serves as the Chief Operating Officer and Chief Quality Officer at Amniotics AB since 2017. Their responsibilities include overseeing operations and ensuring quality standards are met. Prior to this, they worked as a Senior Scientist at Amniotics AB from 2017 to 2018.
Before joining Amniotics AB, Jan held the position of Senior Scientist and Project Manager at Xintela AB from 2013 to 2018. Jan F played a crucial role in managing stem cell projects and was responsible for research expertise in the company.
In 2013, Jan worked as the Chief Medical Staff at Region Skåne. Jan F also has experience working as an Associate Professor at University of Copenhagen from 2003 to 2011, where their research areas included cell fusion, cancer, antibody production, and extracellular matrix biology. Additionally, they served as a Section Leader for Anatomy and Cell biology at the university.
Jan's earlier experience includes working as an Associate Professor at Lund University from 1999 to 2003 and as a Post-doctoral fellow at Abteilung Proteinchemie, Max-Planck-Institut für Biochemie from 1996 to 1999.
Jan F Talts has an extensive education history in the field of biology. They obtained a B.Sc in Biology from Uppsala University from 1984 to 1987. Following this, they went on to earn a Ph.D in Animal Physiology from Uppsala University, completing their studies from 1984 to 1996. Jan F Talts further pursued their education by becoming a Docent in Cell and Molecular Biology at Lund University until 2001. Apart from their academic achievements, they also hold a certification as an ECA Certified Quality Assurance Manager from the European Compliance Academy.
This person is not in any teams
Amniotics AB
Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the University Hospital of Lund, the company ispioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (MPA in Sweden), approved GMP (Good Manufacturing Practice) manufacturing facility to produce Advanced therapy medicinal products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.